ASX Announcement

IMRICOR TO PRESENT AT BELL POTTER HEALTHCARE CONFERENCE

25 November 2020 – Minneapolis, United States – Imricor Medical Systems, Inc. (**Company** or **Imricor**) (**ASX:IMR**) the global leader in MRI-guided cardiac ablation products, advises that Chair and CEO, Steve Wedan will present at the Bell Potter Healthcare conference on Thursday 26 November 2020 AEDT, live from Imricor's iCMR lab in Minneapolis.

The attached slides will be included in the presentation.

Authorised for release by Steve Wedan, Executive Chair, President, and CEO.

ENDS

Further Information

Investors:
Steve Wedan
Executive Chair, President and CEO
Email: steve.wedan@imricor.com

Investors & Australian Media:
Carrie Barrack
Senior Advisor, Cato & Clive
Email: carrie@catoandclive.com
Mobile: +61 422 464 028

Rest of World Media:
Nick Twohy
Director of Marketing, Imricor
Email: nick.twohy@imricor.com
Phone: +1 952 818 8407

About Imricor

Imricor Medical Systems, Inc. (ASX:IMR) is a leading developer of innovative MRI-compatible medical devices which can be used to carry out MRI-guided cardiac catheter ablation procedures. Headquartered in the US, Imricor seeks to make a meaningful impact on patients, healthcare professionals, and healthcare facilities around the world by increasing the success rates and bringing down the overall costs of cardiac catheter ablation procedures.

Imricor's Products

Imricor is a pioneer and leader in developing MRI-compatible products for cardiac catheter ablation procedures, and believes it is the first company in the world to bring commercially viable and safe MRI-compatible products to the cardiac catheter ablation market.

The Vision-MR Ablation Catheter is the Company's prime product offering, specifically designed to work under real-time MRI guidance, with the intent of enabling higher success rates along with a faster and safer treatment compared to conventional procedures using x-ray guided catheters. The Vision-MR Ablation Catheter has been approved in the European Union with an indication for treating type 1 atrial flutter. Imricor intends to seek approval for expanded indications in the future. The Company is also in the early stages of pursuing the required regulatory approvals to place its key products on the market in Australia and the U.S.

The Company has also obtained approval within the EU for the sale of the Advantage-MR EP Recorder/Stimulator System and its consumable product, the Vision-MR Dispersive Electrode.

Imricor sells its capital and consumable products to hospitals and clinics for use in Interventional Cardiac Magnetic Resonance Imaging (iCMR) labs, in which ablation procedures using the Vision-MR Ablation Catheter can be performed. An iCMR lab is an interventional lab that is fitted with MRI equipment for use in cardiac diagnostic and interventional procedures. The installation of iCMR labs is driven primarily by MRI equipment vendors working collaboratively with Imricor. Vendors such as Koninklijke Philips N.V. and Siemens Healthcare GmbH help to target certain sites and support the design and construction of iCMR labs for those sites.

Foreign Ownership Restrictions

Imricor's CHESS Depositary Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, EU commercial market acceptance and EU. sales of our product as well as our expectations with respect to our ability to develop and commercialise new products. Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Imricor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Imricor may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

Bell Potter Healthcare Conference

26 November 2020

Disclaimer

The material contained in this presentation is intended to be general background information on Imricor Medical Systems Inc ("Imricor") and its activities.

The information is supplied in summary form and is therefore not necessarily complete. It is not intended that it be relied upon as advice to investors or potential investors, who should consider seeking independent professional advice depending upon their specific investment objectives, financial situation or particular needs. The material contained in this presentation may include information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information.

Unless otherwise noted, financial information in this presentation has been prepared in accordance with accounting principles generally accepted in the U.S. (US GAAP) and are denominated in US dollars.

This presentation may contain statements that constitute "forward-looking statements" within the meaning of Section 21E of the US Securities Exchange Act of 1934. Forward-looking statements are statements about matters that are not historical facts. Forward-looking statements appear in a number of places in this presentation and include statements regarding our intent, belief or current expectations with respect to our business and operations, market conditions, results of operations and financial condition.

We use words such as 'will', 'may', 'expect', 'intend', 'seek', 'would', 'should', 'could', 'continue', 'plan', 'estimate', 'anticipate', 'believe', 'probability', 'risk', 'aim', or other similar words to identify forward-looking statements. These forward-looking statements reflect our current views with respect to future events and are subject to change, certain risks, uncertainties and assumptions which are, in many instances, beyond our control, and have been made based upon management's expectations and beliefs concerning future developments and their potential effect upon us. There can be no assurance that future developments will be in accordance with our expectations or that the effect of future developments on us will be those anticipated. Actual results could differ materially from those which we expect, depending on the outcome of various factors. Factors that may impact on the forward-looking statements made include, but are not limited to, those described in the section titled 'Risk factors' in Imricor's prospectus dated 7 August 2019. When relying on forward-looking statements to make decisions with respect to us, investors and others should carefully consider such factors and other uncertainties and events. We are under no obligation to update any forward-looking statements contained in this presentation, whether as a result of new information, future events or otherwise, after the date of this presentation.

This presentation does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States or in any other jurisdiction.

A pioneer and global leader in developing MRI-guided cardiac ablation products

Imricor is an innovative US based medical device company and is the only company in the world to bring commercially viable and safe MRI-compatible products to the cardiac catheter ablation market

Heart arrythmias and conventional treatment options

In the absence of MRI-compatible catheter ablation devices, physicians have been unable to take advantage of the potential benefits related to MRI guided ablation procedures for treating arrhythmias

Arrhythmias

- An arrhythmia is an abnormal heart rhythm
- Certain untreated arrhythmias can lead to serious cardiac conditions, such as blood clotting, stroke and/or death
- Rising global incidence of arrhythmias driven by secular demographic trends, such as aging population and increased occurrence of hypertension, obesity and diabetes

Conventional Treatment Options

- Conventional catheter ablation procedures performed guided by x-ray and aided by 3D mapping and tracking tools
- Antiarrhythmic drugs which focus on changing the electrical properties of cardiac tissue
- Implantable devices such as a pacemaker or defibrillator

The problems we are trying to solve through MRI guided ablation procedures

Visualisation

Procedure effectiveness

Cost

Procedure time

Safety

Existing Challenges

- Poor visualisation
- Permanency of legions not determined

- Negative impact on single procedures success rates
- Vary from 38% to over 95%

- Repeat procedures result in higher medical costs

- Conventional 3D mapping systems add procedure time
- AFL ablation procedure 88 minute on average

- Radiation exposure during x-ray guided ablations
- Protective garments worn can lead to occupational injuries

Imricor's Solution

- Real-time imaging gives visibility to soft tissue and non-permanent lesions
- 2D and 3D imaging available

- Reduced likelihood of a repeat procedure
- 100% success rate for AFL procedures[1]

- Increased effectiveness, fewer procedures and lower overall treatment cost

- Average procedure time for MRI-guided AFL ablations is 48 minutes
- Enables the physician to perform more procedures

- MRI generates no radiation removing the risk of radiation and need for heavy protective garments

1. Imricor's clinical trial delivered a 100% chronic success rate for AFL procedures

Our business model

Today Imricor primarily generates revenue from the sale of its capital equipment and consumable products



A strong and growing market in cardiac ablation

A large global addressable market with high growth potential supported by favourable growth drivers

Drivers of Global Catheter Ablation Market

- Increased incidence of cardiac disease
- Shift towards minimally invasive procedures
- Cost effectiveness of catheter ablation as treatment option

EU[1] and US Cardiac Ablation Market



Sources:
Millennium Research Group *Electrophysiology Mapping and Ablation Devices Europe 2021* July 2020
Millennium Research Group *Electrophysiology Mapping and Ablation Devices US 2021* June 2020

1. EU represented by five countries: UK, Germany, France, Spain, Italy

Core strategies to drive future growth

Imricor's strategy is focused on the two drivers that are key to revenue growth – the number of iCMR labs and the number of procedures performed using Imricor's consumables in each lab

Go to market strategies

- Collaborative sales distribution agreement with Philips
- Strategic relationship with Siemens
- Growing awareness through sales and marketing activities
- Engagement with Key Opinion Leaders
- Comprehensive training and support at clinical sites

Geographic expansion



- CE mark approval enables the sale of products in the EU
- Strategy to obtain FDA approval in the US well advanced and targeting clinical trials in 2021-2022
- Local agent to be selected to support TGA approval in Australia

Expanded indications



- Ablation catheter has CE mark approval for the treatment of atrial flutter
- Atrial flutter comprises only 23% of ablation procedures in the EU
- Planning to commence clinical trials to expand CE mark approval to other indications in 2021

Expanded Product Range

- Diagnostic catheter under development to support margin improvement
- Steerable sheath and transceptal needle supporting expanded indications
- NIH contract to develop a device to biopsy the inner walls of the heart guided by MRI
- Other opportunities beyond cardiac ablation

What to learn more about Imricor?

Transforming Cardiac Ablation Procedures

Imricor corporate procedural video

https://vimeo.com/438663377

Experience the Future of Cardiac Ablation

Dr. Thomas Gaspar and Dr. Stefan Ulbrich from the Dresden Heart Centre discuss their successes performing cardiac ablation utilising real-time MR imaging

https://www.youtube.com/watch?v=qjXiMWuuvDI

Early Results and Experiences for iCMR in Atrial Flutter

Jakob Tomala, Heart Centre Dresden

Ablation Center of the Future

Ivo Van Der Bilt, Haga Hospital

https://www.magnetomworld.siemens-healthineers.com/magnetom-world-summit/recordings

Contact information

Investors:

Steve Wedan
Executive Chair, President & CEO
Email: steve.wedan@imricor.com

Carrie Barrack
Cato & Clive
Email: carrie@catoandclive.com

Website:

https://imricor.com/

Follow us: